A Historical Review of Brain Drug Delivery

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Jun 24

PMID 35745855

Authors

William M Pardridge

Affiliations

Soon will be listed here.

Abstract

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914, that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood-brain barrier (BBB). Owing to restricted transport across the BBB, FDA-approved drugs for the CNS have been generally limited to lipid-soluble small molecules. Drugs that do not cross the BBB can be re-engineered for transport on endogenous BBB carrier-mediated transport and receptor-mediated transport systems, which were identified during the 1970s-1980s. By the 1990s, a multitude of brain drug delivery technologies emerged, including trans-cranial delivery, CSF delivery, BBB disruption, lipid carriers, prodrugs, stem cells, exosomes, nanoparticles, gene therapy, and biologics. The advantages and limitations of each of these brain drug delivery technologies are critically reviewed.

Citing Articles

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

Trunfio M, Scutari R, Fox V, Vuaran E, Dastgheyb R, Fini V bioRxiv. 2025; .

PMID: 40060671 PMC: 11888432. DOI: 10.1101/2025.02.28.640732.

Autologous cord blood individualized supplements in autistic spectrum disorder: CORDUS study results.

Stancioiu F, Bogdan R, Ivanescu B, Dumitrescu R World J Clin Pediatr. 2025; 14(1):96643.

PMID: 40059901 PMC: 11686574. DOI: 10.5409/wjcp.v14.i1.96643.

Alanine and glutathione targeting of dopamine- or ibuprofen-coupled polypeptide nanocarriers increases both crossing and protective effects on a blood-brain barrier model.

Meszaros M, Phan T, Vigh J, Porkolab G, Kocsis A, Szecsko A Fluids Barriers CNS. 2025; 22(1):18.

PMID: 39972353 PMC: 11837687. DOI: 10.1186/s12987-025-00623-2.

Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery.

Schwinghamer K, Siahaan T J Nanotheranostics. 2025; 4(4):463-479.

PMID: 39897432 PMC: 11784990. DOI: 10.3390/jnt4040020.

Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein.

Cuypers M, Jaspers T, Clerckx J, Leekens S, Cawthorne C, Bormans G Fluids Barriers CNS. 2025; 22(1):11.

PMID: 39885527 PMC: 11783731. DOI: 10.1186/s12987-025-00624-1.

References

Cordon-Cardo C, OBrien J, CASALS D, Biedler J, Melamed M, Bertino J . Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989; 86(2):695-8. PMC: 286540. DOI: 10.1073/pnas.86.2.695. View

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G . Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther. 2016; 8(1):14. PMC: 4822297. DOI: 10.1186/s13195-016-0181-2. View

Molino Y, David M, Varini K, Jabes F, Gaudin N, Fortoul A . Use of LDL receptor-targeting peptide vectors for and cargo transport across the blood-brain barrier. FASEB J. 2017; 31(5):1807-1827. DOI: 10.1096/fj.201600827R. View

Bies C, Lehr C, Woodley J . Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev. 2004; 56(4):425-35. DOI: 10.1016/j.addr.2003.10.030. View

Mullard A . ALS antisense drug falters in phase III. Nat Rev Drug Discov. 2021; 20(12):883-885. DOI: 10.1038/d41573-021-00181-w. View

Morris M, Rodriguez-Cruz V, Felmlee M . SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers. AAPS J. 2017; 19(5):1317-1331. PMC: 6467070. DOI: 10.1208/s12248-017-0110-8. View

Huwyler J, Pardridge W . Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 1998; 70(2):883-6. DOI: 10.1046/j.1471-4159.1998.70020883.x. View

Condori J, Acosta W, Ayala J, Katta V, Flory A, Martin R . Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion. Mol Genet Metab. 2016; 117(2):199-209. PMC: 6116835. DOI: 10.1016/j.ymgme.2015.12.002. View

Duffy K, Pardridge W, Rosenfeld R . Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988; 37(2):136-40. DOI: 10.1016/s0026-0495(98)90007-5. View

10.

Allen D, Smith Q . Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem. 2001; 76(4):1032-41. DOI: 10.1046/j.1471-4159.2001.00093.x. View

11.

Larson S, Carrasquillo J, Cheung N, Press O . Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015; 15(6):347-60. PMC: 4798425. DOI: 10.1038/nrc3925. View

12.

Shi N, Zhang Y, Zhu C, Boado R, Pardridge W . Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A. 2001; 98(22):12754-9. PMC: 60126. DOI: 10.1073/pnas.221450098. View

13.

Thorne R, Emory C, Ala T, Frey 2nd W . Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995; 692(1-2):278-82. DOI: 10.1016/0006-8993(95)00637-6. View

14.

Sohlenius-Sternbeck A . Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro. 2006; 20(8):1582-6. DOI: 10.1016/j.tiv.2006.06.003. View

15.

Valtonen S, Timonen U, TOIVANEN P, Kalimo H, Kivipelto L, HEISKANEN O . Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997; 41(1):44-8; discussion 48-9. DOI: 10.1097/00006123-199707000-00011. View

16.

Bersani M, Rizzuti M, Pagliari E, Garbellini M, Saccomanno D, Moulton H . Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model. Mol Ther. 2021; 30(3):1288-1299. PMC: 8899506. DOI: 10.1016/j.ymthe.2021.11.012. View

17.

Zou D, Wang W, Lei D, Yin Y, Ren P, Chen J . Penetration of blood-brain barrier and antitumor activity and nerve repair in glioma by doxorubicin-loaded monosialoganglioside micelles system. Int J Nanomedicine. 2017; 12:4879-4889. PMC: 5511015. DOI: 10.2147/IJN.S138257. View

18.

Chand D, Mohr F, McMillan H, Tukov F, Montgomery K, Kleyn A . Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2020; 74(3):560-566. DOI: 10.1016/j.jhep.2020.11.001. View

19.

Bogousslavsky J, Victor S, Salinas E, Pallay A, Donnan G, Fieschi C . Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis. 2002; 14(3-4):239-51. DOI: 10.1159/000065683. View

20.

Schumann T, Konig J, Henke C, Willmes D, Bornstein S, Jordan J . Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. Pharmacol Rev. 2019; 72(1):343-379. DOI: 10.1124/pr.118.015735. View